Pediatric Long-Term Studies Needed To Follow Drug Effects On Development
Pediatric clinical trials should be followed-up by long-term safety and efficacy studies to monitor drugs' effects later in life, Center for Drug Evaluation & Research Deputy Director for Review Management Murray Lumpkin, MD, suggested at a meeting on rational pediatric therapeutics sponsored by the Institute of Medicine in Washington, D.C.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth